207 related articles for article (PubMed ID: 11094118)
1. Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive.
Myhr KM; Ross C; Nyland HI; Bendtzen K; Vedeler CA
Neurology; 2000 Nov; 55(10):1569-72. PubMed ID: 11094118
[TBL] [Abstract][Full Text] [Related]
2. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
Antonelli G; Simeoni E; Bagnato F; Pozzilli C; Turriziani O; Tesoro R; Di Marco P; Gasperini C; Fieschi C; Dianzani F
J Neurol Sci; 1999 Oct; 168(2):131-6. PubMed ID: 10526196
[TBL] [Abstract][Full Text] [Related]
3. Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration.
Khan OA; Xia Q; Bever CT; Johnson KP; Panitch HS; Dhib-Jalbut SS
Neurology; 1996 Jun; 46(6):1639-43. PubMed ID: 8649563
[TBL] [Abstract][Full Text] [Related]
4. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG).
Rudick RA; Simonian NA; Alam JA; Campion M; Scaramucci JO; Jones W; Coats ME; Goodkin DE; Weinstock-Guttman B; Herndon RM; Mass MK; Richert JR; Salazar AM; Munschauer FE; Cookfair DL; Simon JH; Jacobs LD
Neurology; 1998 May; 50(5):1266-72. PubMed ID: 9595973
[TBL] [Abstract][Full Text] [Related]
5. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations.
Bertolotto A; Malucchi S; Milano E; Castello A; Capobianco M; Mutani R
Immunopharmacology; 2000 Jul; 48(2):95-100. PubMed ID: 10936507
[TBL] [Abstract][Full Text] [Related]
6. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS.
Trojano M; Avolio C; Liuzzi GM; Ruggieri M; Defazio G; Liguori M; Santacroce MP; Paolicelli D; Giuliani F; Riccio P; Livrea P
Neurology; 1999 Oct; 53(7):1402-8. PubMed ID: 10534242
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis.
Kivisäkk P; Alm GV; Fredrikson S; Link H
Eur J Neurol; 2000 Jan; 7(1):27-34. PubMed ID: 10809912
[TBL] [Abstract][Full Text] [Related]
8. Interaction of PEGylated interferon-beta with antibodies to recombinant interferon-beta.
Gilli F; De La Torre AL; Royce DB; Pachner AR
Int Immunopharmacol; 2018 Sep; 62():1-6. PubMed ID: 29960044
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive.
Khan OA; Dhib-Jalbut SS
Neurology; 1998 Dec; 51(6):1698-702. PubMed ID: 9855525
[TBL] [Abstract][Full Text] [Related]
10. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
Massart C; Gibassier J; de Seze J; Debouverie M; Moreau T; Pelletier J; Vermersch P; Edan G
Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
[TBL] [Abstract][Full Text] [Related]
11. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
[TBL] [Abstract][Full Text] [Related]
12. Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients.
Cook SD; Quinless JR; Jotkowitz A; Beaton P;
Neurology; 2001 Sep; 57(6):1080-4. PubMed ID: 11571337
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of an interferon-beta1a product.
Kauffman MA; Sterin-Prync A; Papouchado M; González E; Vidal AJ; Grossberg SE; Chuppa S; Odoriz B; Vrech C; Diez RA; Ferro HH
Int J Immunopathol Pharmacol; 2011; 24(2):499-504. PubMed ID: 21658324
[TBL] [Abstract][Full Text] [Related]
14. Antibodies to interferon beta in patients with multiple sclerosis receiving CinnoVex, rebif, and betaferon.
Zare N; Zarkesh-Esfahani SH; Gharagozloo M; Shaygannejad V
J Korean Med Sci; 2013 Dec; 28(12):1801-6. PubMed ID: 24339712
[TBL] [Abstract][Full Text] [Related]
15. ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-beta.
Brickelmaier M; Hochman PS; Baciu R; Chao B; Cuervo JH; Whitty A
J Immunol Methods; 1999 Jul; 227(1-2):121-35. PubMed ID: 10485260
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of interferon-consensus 1, interferon-alpha 2a, and interferon-beta 1b on HLA expression and lymphoproliferation: a preclinical model for treatment of multiple sclerosis.
Dhib-Jalbut S; Jiang H; Xia Q; Blatt L; Johnson KP; Hilt D
J Interferon Cytokine Res; 1996 Mar; 16(3):195-200. PubMed ID: 8697141
[TBL] [Abstract][Full Text] [Related]
17. Serial immunoprecipitation assays for interferon--(IFN)-beta antibodies in multiple sclerosis patients.
Lampasona V; Rio J; Franciotta D; Furlan R; Avolio C; Fazio R; Lavolpe V; Vincent A; Comi G; Trojano M; Montalban X; Martino G
Eur Cytokine Netw; 2003; 14(3):154-7. PubMed ID: 14656689
[TBL] [Abstract][Full Text] [Related]
18. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.
Gneiss C; Tripp P; Reichartseder F; Egg R; Ehling R; Lutterotti A; Khalil M; Kuenz B; Mayringer I; Reindl M; Berger T; Deisenhammer F
Mult Scler; 2006 Dec; 12(6):731-7. PubMed ID: 17263000
[TBL] [Abstract][Full Text] [Related]
19. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies.
Deisenhammer F; Reindl M; Harvey J; Gasse T; Dilitz E; Berger T
Neurology; 1999 Apr; 52(6):1239-43. PubMed ID: 10214750
[TBL] [Abstract][Full Text] [Related]
20. A case study on the effect of neutralizing antibodies to interferon beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging.
Chiu AW; Ehrmantraut M; Richert ND; Ikonomidou VN; Pellegrini S; McFarland HF; Frank JA; Bagnato F
Clin Exp Immunol; 2007 Oct; 150(1):61-7. PubMed ID: 17666095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]